Hot sectors in a tepid recovery
The energy, finance, technology and healthcare industries are expected to be the hottest areas for dealmaking in 2010. Full Article | Full Coverage
UPDATE 1-Glaxo Q1 profits down 1 pct, hit by strong pound
(Adds further details on products, pipeline)
LONDON, April 25 (Reuters) - GlaxoSmithKline Plc (GSK.L) profits dipped 1 percent in the first quarter, as sales were hit by the strength of sterling and the loss of patent protection on key medicines, Europe's biggest drugmaker said on Wednesday.
Pretax profits in the three months to March 31 totalled 2.14 billion pounds
($4.3 billion) on sales down 4 percent at 5.59 billion, equivalent to earnings per share of 27 pence.
The average EPS forecast had been 26p in a Reuters poll of 14 analysts, but the profit numbers were boosted by a one-off gain of 207 million pounds related in part to the settlement with Swiss drugmaker Roche (ROG.VX) over blood pressure drug carvedilol.
Sales, meanwhile, came in below forecasts of 5.75 billion and Glaxo shares erased earlier gains to stand 0.8 percent lower at 14.60 pounds by 1115 GMT.
For the full year, Glaxo maintained its forecast of earnings growth of between 8 and 10 percent at constant exchange rates. EPS growth in the first quarter advanced 14 percent on this basis.
Glaxo's business is at a turning point, with its two biggest sellers -- Advair and diabetes treatment Avandia -- facing a slowdown in growth, while the company hopes to revive its fortunes by bringing new drugs on stream.
The British-based group last month won approval for a novel breast cancer pill called Tykerb and is hoping for a green light later this year for cervical cancer vaccine Cervarix, taking it deeper into the fast-growing oncology field.
Chief Executive Jean-Pierre Garnier said the company was making good progress on getting its new products to market, with 10 filed, approved or launched in the first quarter of 2007.
Worries over existing medicines and uncertainty about prospects for the pipeline mean Glaxo shares trade at a discount to the sector. The stock fetches around 14.5 times forecast 2007 earnings, against an average for the European healthcare sector .SXDP of 17, according to Reuters data.
((Reporting by Ben Hirschler, editing by Quentin Bryar; email: ben.hirschler@reuters.com; Reuters Messaging: ben.hirschler.reuters.com@reuters.net; +44 20 7542 5082))
((Reporting by Ben Hirschler; Editing by Mark Potter, email: ben.hirschler@reuters.com; Reuters Messaging: ben.hirschler.reuters.com@reuters.net; +44 20 7542 5082))
($1=.4991 Pound) Keywords: GLAXO RESULTS/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nL25218309
